Reviews Supplements B+L CE Monograph : Page 1

2 CE Credits (COPE Approved) Topical Corticosteroids in the Treatment of Ocular Infl ammation Important characteristics and points to consider when prescribing this class of drug, particularly in light of a new product that’s making a big impact on patient care. C orticosteroids are an integral part of ophthal-mic care. When properly prescribed, topical steroids pro-vide tremendous benefi ts, such as controlling infl ammation and scarring, preventing vision loss and enabling a more rapid return to comfortable contact lens wear. However, long-term use can in-crease intraocular pressure (IOP), cause cataracts and potentiate infection. These side eff ects are rare with traditional ketone ste-roids and are even rarer with the use of ester-based steroids. Our four renowned panelists, representing roughly 125 years of intensive clinical experience using corticosteroids, fully embrace the clinical virtues of this class of drugs. In the following pages they’ll share their expertise in the use of ocular corticosteroids, highlighting the performance of one of the newest drugs in this class, loteprednol etabonate oph-thalmic gel 0.5% (Lotemax Gel, Bausch + Lomb). Their discussion begins with a broad perspective Release Date: September 2013 Expiration Date: September 30, 2014 Goal Statement: Corticosteroids are an integral part of ophthalmic care that can provide tremendous benefits, such as controlling inflammation and scarring, preventing vision loss and enabling a more rapid return to comfortable contact lens wear. The ultimate goal is to make a proper diagnosis: is it an infection or inflamma-tion? Inflammation is far more common, and the ultimate product to curtail inflammation is a steroid. This educational activity will review the use of topical corticosteroids, including one of the newer drugs in this class, loteprednol etabonate ophthalmic gel 0.5% (Lotemax). Faculty/Editorial Board: Jimmy D. Bartlett, OD, DOS, ScD; Paul M. Karpecki, OD; Ron Melton, OD, FAAO; Randall K. Thomas, OD, MPH, FAAO Sponsored by Credit Statement: This course is COPE approved for 2 hours of CE credit. COPE ID is 38753-PH. Please check your state licens-ing board to see if this approval counts toward your CE require-ment for relicensure. Joint-sponsorship Statement: This continuing education course is joint sponsored by the University of Alabama School. Disclosure Statement: Dr. Bartlett serves as a consultant and/ or speaker to Bausch + Lomb and Tropical CE. Dr. Karpecki is a consultant for Bausch + Lomb and Alcon. Dr. Melton is consultant to, on the speakers bureau of or involved in research for: Alcon, Bausch + Lomb, ICare, Jobson Medical Information and Nicox. Dr. Thomas has direct financial and/ or proprietary interests in Alcon, Bausch + Lomb, Carl Zeiss, ICare and Merck. Supported by an educational grant from This enduring activity contains discussion of published and/or investigational uses of agents that are not indicated by the FDA. Off -label use of a medication or a biological is defi ned as use for an indication, or in a manner, for which FDA approval has not yet been obtained and which is therefore not included on the FDA-approved label or product packaging. Please refer to the offi cial prescribing information for each product for discussion of approved indications, contraindications and warnings. Practitioners should critically assess the information herein and are encouraged to consult appropriate resources for any product or device mentioned in this program. The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic based on the best available evidence. REVIEW OF OPTOMETRY SEPTEMBER 2013 1

Next Page


Publication List
Using a screen reader? Click Here